title: High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, Washington; University of Washington, Seattle, Washington. Electronic address: podonnel@fhcrc.org.
authors.forename: Paul
authors.initials: P
authors.lastname: O'Donnell
authors.affiliation: Guy's and St. Thomas' NHS Hospitals Foundation Trusts, London, United Kingdom; Department of Hematological Medicine, King's College Hospital, London, United Kingdom.
authors.forename: Kavita
authors.initials: K
authors.lastname: Raj
authors.affiliation: Guy's and St. Thomas' NHS Hospitals Foundation Trusts, London, United Kingdom; Department of Hematological Medicine, King's College Hospital, London, United Kingdom; King's College, London, United Kingdom.
authors.forename: Antonio
authors.initials: A
authors.lastname: Pagliuca
mesh_terms: D016026:Bone Marrow Transplantation / Q000009:adverse effects; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005334:Fever / Q000209:etiology / Q000276:immunology / Q000473:pathology*; D006086:Graft vs Host Disease / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D006239:Haplotypes; D019337:Hematologic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006650:Histocompatibility Testing; D006801:Humans; D019653:Myeloablative Agonists / Q000627:therapeutic use; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D061349:Unrelated Donors
chemical_list: D019653:Myeloablative Agonists; D003520:Cyclophosphamide